ticlopidine has been researched along with Coronary Stenosis in 146 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Coronary Stenosis: Narrowing or constriction of a coronary artery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials." | 9.19 | Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. ( Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis." | 7.77 | Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011) |
| "We report our experience with a case of isolated profound thrombocytopenia after clopidogrel (thienopyridine) administration." | 7.72 | [Clopidogrel and thrombopenia. A case report]. ( Beygui, F; Elalamy, I; Helft, G; Khellaf, C; Laudy, C; Le Feuvre, C; Metzger, JP; Monnet de Lorbeau, B; Ounissi, F; Tran, D, 2003) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials." | 5.19 | Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. ( Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R, 2014) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome." | 5.17 | Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). ( Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C, 2013) |
| "In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone." | 5.11 | Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005) |
| " Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting." | 3.81 | Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "A 36 year-old man, who had undergone a paclitaxel-eluting stent deployment into the left main (LM) coronary artery three years before, was admitted after successful resuscitation following out-of-hospital cardiac arrest due to an acute ST-segment elevation myocardial infarction." | 3.79 | Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery. ( Janus, M; Lesiak, M; Lukawski, K; Prech, M, 2013) |
| "Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis." | 3.77 | Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( Byron, KA; Dear, AE; Dick, RJ, 2011) |
| "We report a 56-year-old patient who had been taking antihypertensive medication in combination with prophylactic aspirin for 19 years who was diagnosed with stable angina with significant coronary artery stenosis on angiography." | 3.75 | Spontaneous spinal epidural hematoma: an urgent complication of adding clopidogrel to aspirin therapy. ( Chung, HS; Kim, JH; Kwon, TH; Moon, HJ; Park, YK, 2009) |
| "We describe a case of an 81-year-old man with acute ST-elevation myocardial infarction (STEMI), who received a loading dose of clopidogrel (300 mg) and aspirin (ASA) (300 mg) prior to primary coronary intervention of critical left anterior descending coronary artery stenosis." | 3.74 | [Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report]. ( Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M, 2007) |
| " The patient experienced a coronary stent thrombosis possibly due to discontinuation of clopidogrel prior to urologic surgery." | 3.74 | Late coronary stent thrombosis complicating urologic surgery. ( de Korte, FI; Ten Berg, JM; van Werkum, JW; Vijverberg, PL, 2008) |
| "Statins are frequently given in conjunction with clopidogrel for prophylaxis and therapy of coronary heart disease." | 3.74 | [Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention]. ( Gawaz, M; Geisler, T; Paterok, M; Zürn, CS, 2008) |
| "5% in the ticlopidine group, and myocardial infarction (MI) was also reduced in the clopidogrel group (4." | 3.72 | Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. ( Albirini, A; Aronow, HD; Bhatt, DL; Cura, FA; Ellis, SG; L'Allier, PL; Schneider, JP; Topol, EJ, 2003) |
| "We report our experience with a case of isolated profound thrombocytopenia after clopidogrel (thienopyridine) administration." | 3.72 | [Clopidogrel and thrombopenia. A case report]. ( Beygui, F; Elalamy, I; Helft, G; Khellaf, C; Laudy, C; Le Feuvre, C; Metzger, JP; Monnet de Lorbeau, B; Ounissi, F; Tran, D, 2003) |
| "Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels." | 2.76 | Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. ( Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011) |
| "We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA)." | 2.71 | The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. ( Bliden, KP; Gurbel, PA; Hayes, KM; Herzog, WR; Tantry, US; Yoho, JA, 2005) |
| "Hemodynamic significance of all coronary stenoses was assessed with Fractional Flow Reserve (FFR)." | 1.39 | The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease. ( de Groot, PG; Hillaert, MA; Pasterkamp, G; Pijls, NH; Roest, M; Rutten, B; Sels, JW; van Holten, TC; Waltenberger, J, 2013) |
| "Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs." | 1.37 | Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Isolated splenic infarction as a complication of the procedure is extreme rare." | 1.35 | Athero-embolic isolated splenic infarction following left cardiac catheterization. ( Hussein, A; Irani, F; Kasmani, R; Mohan, G, 2009) |
| "Serious allergic reactions have also been reported; (6) In most cases, especially when the risk of restenosis is low or moderate, it is better to use a bare metal stent." | 1.35 | Drug-eluting coronary stents: many meta-analyses, little benefit. ( , 2009) |
| " Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted." | 1.35 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. ( Endemann, S; Ernst, A; Gollapudi, RR; Levisay, JP; Price, MJ; Sawhney, NS; Schatz, RA; Stinis, CT; Teirstein, PS; Valencia, R, 2008) |
| " We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up." | 1.34 | Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "Pretreatment with parecoxib (20 mg/kg) almost doubled shear stress-induced platelet aggregation (188% vs." | 1.33 | Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. ( Borgdorff, P; Paulus, WJ; Tangelder, GJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 99 (67.81) | 29.6817 |
| 2010's | 47 (32.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joo, HJ | 1 |
| Park, JY | 1 |
| Hong, SJ | 1 |
| Kim, KA | 1 |
| Lee, SH | 2 |
| Cho, JY | 1 |
| Park, JH | 1 |
| Yu, CW | 1 |
| Lim, DS | 2 |
| Parodi, G | 1 |
| Nusdeo, G | 1 |
| Terrosu, P | 1 |
| Prech, M | 1 |
| Janus, M | 1 |
| Lukawski, K | 1 |
| Lesiak, M | 1 |
| Gurbel, PA | 7 |
| Tantry, US | 6 |
| Kunadian, V | 1 |
| James, SK | 1 |
| Wojdyla, DM | 1 |
| Zorkun, C | 1 |
| Wu, J | 1 |
| Storey, RF | 1 |
| Steg, PG | 1 |
| Katus, H | 1 |
| Emanuelsson, H | 1 |
| Horrow, J | 1 |
| Maya, J | 1 |
| Wallentin, L | 1 |
| Harrington, RA | 3 |
| Gibson, CM | 1 |
| Stone, GW | 1 |
| Witzenbichler, B | 2 |
| Weisz, G | 1 |
| Rinaldi, MJ | 1 |
| Neumann, FJ | 2 |
| Metzger, DC | 1 |
| Henry, TD | 1 |
| Cox, DA | 1 |
| Duffy, PL | 1 |
| Mazzaferri, E | 1 |
| Xu, K | 1 |
| Parise, H | 1 |
| Kirtane, AJ | 1 |
| Brodie, BR | 1 |
| Mehran, R | 2 |
| Stuckey, TD | 1 |
| Musumeci, G | 1 |
| Limbruno, U | 1 |
| Sels, JW | 1 |
| Rutten, B | 1 |
| van Holten, TC | 1 |
| Hillaert, MA | 1 |
| Waltenberger, J | 1 |
| Pijls, NH | 1 |
| Pasterkamp, G | 1 |
| de Groot, PG | 1 |
| Roest, M | 1 |
| Ho, HH | 2 |
| Er Ching, M | 1 |
| Ong, PJ | 2 |
| Ooi, YW | 2 |
| Loh, JP | 1 |
| Torguson, R | 1 |
| Pendyala, LK | 1 |
| Omar, A | 1 |
| Chen, F | 1 |
| Satler, LF | 1 |
| Pichard, AD | 1 |
| Waksman, R | 4 |
| Fukuyama, K | 1 |
| Fujikawa, T | 1 |
| Kuramitsu, S | 1 |
| Tanaka, A | 2 |
| Schulz, S | 1 |
| Richardt, G | 1 |
| Laugwitz, KL | 1 |
| Morath, T | 1 |
| Neudecker, J | 1 |
| Hoppmann, P | 1 |
| Gershlick, AH | 4 |
| Tölg, R | 1 |
| Anette Fiedler, K | 1 |
| Abdel-Wahab, M | 1 |
| Kufner, S | 1 |
| Schneider, S | 1 |
| Schunkert, H | 1 |
| Ibrahim, T | 1 |
| Mehilli, J | 2 |
| Kastrati, A | 2 |
| López Mínguez, JR | 1 |
| Nogales Asensio, JM | 1 |
| Doncel Vecino, LJ | 1 |
| Sandoval, J | 1 |
| Romany, S | 1 |
| Martínez Romero, P | 1 |
| Fernández Díaz, JA | 1 |
| Fernández Portales, J | 1 |
| González Fernández, R | 1 |
| Martínez Cáceres, G | 1 |
| Merchán Herrera, A | 1 |
| Alfonso Manterola, F | 1 |
| Une, D | 1 |
| Al-Atassi, T | 1 |
| Kulik, A | 1 |
| Voisine, P | 1 |
| Le May, M | 1 |
| Ruel, M | 1 |
| Nishimiya, K | 1 |
| Matsumoto, Y | 1 |
| Uzuka, H | 1 |
| Oyama, K | 1 |
| Taruya, A | 1 |
| Ogata, T | 1 |
| Hirano, M | 1 |
| Shindo, T | 1 |
| Hanawa, K | 1 |
| Hasebe, Y | 1 |
| Hao, K | 1 |
| Tsuburaya, R | 1 |
| Takahashi, J | 1 |
| Miyata, S | 1 |
| Ito, K | 1 |
| Akasaka, T | 1 |
| Shimokawa, H | 1 |
| Yang, M | 1 |
| Bai, X | 1 |
| Xu, J | 2 |
| Ni, J | 1 |
| Tang, J | 1 |
| Zeng, Y | 1 |
| Fang, Q | 1 |
| Azzalini, L | 1 |
| Al-Hawwas, M | 1 |
| L'Allier, PL | 2 |
| Shi, H | 1 |
| Lee, CH | 1 |
| Chan, MY | 1 |
| Low, AF | 1 |
| Teo, SG | 1 |
| Chan, KH | 1 |
| Sethi, R | 1 |
| Richards, AM | 1 |
| Tan, HC | 1 |
| Khan, JN | 1 |
| Greenwood, JP | 1 |
| Nazir, SA | 1 |
| Lai, FY | 1 |
| Dalby, M | 1 |
| Curzen, N | 1 |
| Hetherington, S | 1 |
| Kelly, DJ | 1 |
| Blackman, D | 1 |
| Peebles, C | 1 |
| Wong, J | 1 |
| Flather, M | 1 |
| Swanton, H | 1 |
| McCann, GP | 1 |
| Seo, JB | 1 |
| Shin, DH | 1 |
| Park, KW | 3 |
| Koo, BK | 3 |
| Gwon, HC | 2 |
| Jeong, MH | 1 |
| Seong, IW | 1 |
| Rha, SW | 3 |
| Yang, JY | 1 |
| Park, SJ | 3 |
| Yoon, JH | 1 |
| Han, KR | 2 |
| Park, JS | 2 |
| Hur, SH | 3 |
| Tahk, SJ | 1 |
| Kim, HS | 4 |
| Cho, MH | 1 |
| Shin, DW | 1 |
| Yun, JM | 1 |
| Shin, JH | 1 |
| Lee, SP | 1 |
| Lee, H | 2 |
| Lim, YK | 1 |
| Kim, EH | 1 |
| Kim, HK | 1 |
| Shin, ES | 1 |
| Lim, SW | 1 |
| Bae, JW | 1 |
| Jeon, DW | 1 |
| Oh, SK | 1 |
| Kim, BS | 1 |
| Lee, JH | 1 |
| Park, TH | 1 |
| Lee, NH | 1 |
| Jeong, YH | 1 |
| Kim, IS | 1 |
| Choi, BR | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Bonello, L | 1 |
| Camoin-Jau, L | 1 |
| Dignat-George, F | 1 |
| Paganelli, F | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| de la Cruz, KI | 1 |
| Tsai, PI | 1 |
| Cohn, WE | 1 |
| Cooley, DA | 1 |
| Barthwal, R | 1 |
| Herman, BA | 1 |
| Madersbacher, S | 1 |
| Ponholzer, A | 1 |
| Aradi, D | 2 |
| Vorobcsuk, A | 1 |
| Komócsi, A | 2 |
| Hemetsberger, R | 1 |
| Farhan, S | 1 |
| Strehblow, C | 1 |
| Sperker, W | 1 |
| Pavo, I | 1 |
| Petrasi, Z | 1 |
| Hemetsberger, H | 1 |
| Posa, A | 1 |
| Huber, K | 2 |
| Glogar, D | 1 |
| Gyöngyösi, M | 1 |
| Siller-Matula, JM | 1 |
| Lang, I | 1 |
| Christ, G | 2 |
| Jilma, B | 1 |
| Kleiman, NS | 1 |
| Hoshino, K | 1 |
| Horiuchi, H | 1 |
| Tada, T | 1 |
| Tazaki, J | 1 |
| Nishi, E | 1 |
| Kawato, M | 1 |
| Ikeda, T | 1 |
| Yamamoto, H | 1 |
| Akao, M | 1 |
| Furukawa, Y | 1 |
| Shizuta, S | 1 |
| Toma, M | 1 |
| Tamura, T | 1 |
| Saito, N | 1 |
| Doi, T | 1 |
| Ozasa, N | 1 |
| Jinnai, T | 1 |
| Takahashi, K | 1 |
| Watanabe, H | 1 |
| Yoshikawa, Y | 1 |
| Nishimoto, N | 1 |
| Ouchi, C | 1 |
| Morimoto, T | 1 |
| Kita, T | 1 |
| Kimura, T | 1 |
| Jang, SW | 1 |
| Kim, DB | 1 |
| Kwon, BJ | 1 |
| Shin, D | 1 |
| Her, SH | 1 |
| Park, CS | 1 |
| Park, HJ | 1 |
| Park, MW | 1 |
| Cho, EJ | 1 |
| Rho, TH | 1 |
| Kim, JH | 3 |
| Hussein, A | 1 |
| Kasmani, R | 1 |
| Irani, F | 1 |
| Mohan, G | 1 |
| Butler, MJ | 1 |
| Eccleston, D | 1 |
| Clark, DJ | 1 |
| Ajani, AE | 2 |
| Andrianopoulos, N | 1 |
| Brennan, A | 1 |
| New, G | 1 |
| Black, A | 1 |
| Szto, G | 1 |
| Reid, CM | 1 |
| Yan, BP | 1 |
| Shaw, JA | 1 |
| Dart, AM | 1 |
| Duffy, SJ | 1 |
| Cola, C | 1 |
| Brugaletta, S | 1 |
| Martín Yuste, V | 1 |
| Campos, B | 1 |
| Angiolillo, DJ | 5 |
| Sabaté, M | 4 |
| Gao, C | 1 |
| Ren, C | 1 |
| Li, D | 1 |
| Li, L | 1 |
| Moon, HJ | 1 |
| Kwon, TH | 1 |
| Chung, HS | 1 |
| Park, YK | 1 |
| Nesher, N | 1 |
| Singh, SK | 1 |
| Fawzy, HF | 1 |
| Sever, JY | 1 |
| Goldman, BE | 1 |
| Cohen, GN | 1 |
| Laflamme, C | 1 |
| Fremes, SE | 1 |
| Obradović, S | 1 |
| Subota, V | 1 |
| Baskot, B | 1 |
| Dopudja, M | 1 |
| Antonijević, N | 1 |
| Djenić, N | 1 |
| Vukotić, S | 1 |
| Salinger, S | 1 |
| Jovelić, A | 1 |
| Miković, D | 1 |
| Antović, J | 1 |
| Grdenić, A | 1 |
| Gligić, B | 1 |
| Naidu, SS | 1 |
| Turco, MA | 1 |
| Mauri, L | 1 |
| Coolong, A | 1 |
| Popma, JJ | 4 |
| Kereiakes, DJ | 1 |
| Hochholzer, W | 1 |
| Trenk, D | 1 |
| Fromm, MF | 1 |
| Valina, CM | 1 |
| Stratz, C | 1 |
| Bestehorn, HP | 1 |
| Büttner, HJ | 1 |
| Mangiacapra, F | 1 |
| Patti, G | 1 |
| Peace, A | 1 |
| Gatto, L | 1 |
| Vizzi, V | 1 |
| Ricottini, E | 1 |
| D'Ambrosio, A | 1 |
| Muller, O | 1 |
| Barbato, E | 1 |
| Di Sciascio, G | 2 |
| Yong, AS | 1 |
| Pennings, GJ | 1 |
| Chang, M | 1 |
| Hamzah, A | 1 |
| Chung, T | 1 |
| Qi, M | 1 |
| Brieger, D | 1 |
| Behnia, M | 1 |
| Krilis, SA | 1 |
| Ng, MK | 1 |
| Lowe, HC | 3 |
| Kritharides, L | 1 |
| Hahn, JY | 1 |
| Song, YB | 1 |
| Choi, JH | 1 |
| Choi, SH | 1 |
| Lee, SY | 1 |
| Park, HS | 1 |
| Lee, S | 1 |
| Cho, BR | 1 |
| Yoon, J | 1 |
| Drosch, T | 1 |
| Brodoefel, H | 1 |
| Geisler, T | 3 |
| Quell, V | 1 |
| Reimann, A | 1 |
| Heuschmid, M | 1 |
| Schroeder, S | 1 |
| Burgstahler, C | 1 |
| Kozuma, K | 1 |
| Ota, Y | 1 |
| Nagai, Y | 1 |
| Katsuta, Y | 1 |
| Nozaki, E | 1 |
| Onodera, T | 1 |
| Ikari, Y | 1 |
| Kotani, J | 1 |
| Kyo, E | 1 |
| Yokoi, H | 1 |
| Nakamura, M | 1 |
| Dick, RJ | 1 |
| Dear, AE | 1 |
| Byron, KA | 1 |
| Morel, O | 1 |
| El Ghannudi, S | 1 |
| Jesel, L | 1 |
| Radulescu, B | 1 |
| Meyer, N | 1 |
| Wiesel, ML | 1 |
| Caillard, S | 1 |
| Campia, U | 1 |
| Moulin, B | 1 |
| Gachet, C | 1 |
| Ohlmann, P | 1 |
| Egred, M | 1 |
| Niccoli, G | 1 |
| Minelli, S | 1 |
| Cosentino, N | 1 |
| Crea, F | 1 |
| Rideg, O | 1 |
| Magyarlaki, T | 1 |
| Tokés-Füzesi, M | 1 |
| Miseta, A | 1 |
| Kovács, GL | 1 |
| Jeon, KH | 1 |
| Kang, SH | 1 |
| Oh, IY | 1 |
| Cho, HJ | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Park, SK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Stankovic, I | 1 |
| Vlahovic-Stipac, A | 1 |
| Ilic, I | 1 |
| Putnikovic, B | 1 |
| Neskovic, AN | 1 |
| Sangiorgi, GM | 2 |
| Morice, MC | 2 |
| Bramucci, E | 1 |
| Ferlini, M | 1 |
| Grinfeld, L | 1 |
| Petronio, AS | 1 |
| Pierli, C | 1 |
| Iadanza, A | 1 |
| Biondi-Zoccai, G | 1 |
| Colombo, A | 3 |
| Abegunewardene, N | 1 |
| Schmidt, KH | 1 |
| Vosseler, M | 1 |
| Kreitner, KF | 1 |
| Schreiber, LM | 1 |
| Lehr, HA | 1 |
| Gori, T | 1 |
| Münzel, T | 2 |
| Horstick, G | 1 |
| Nakayama, A | 1 |
| Morita, H | 1 |
| Ando, J | 1 |
| Fujita, H | 1 |
| Ohtsu, H | 1 |
| Nagai, R | 1 |
| Canpolat, U | 1 |
| Yorgun, H | 1 |
| Atalar, E | 1 |
| Linares Vicente, JA | 1 |
| Pérez, JO | 1 |
| Lacasa, RC | 1 |
| Jafary, FH | 1 |
| Loh, KK | 1 |
| Tan, JK | 1 |
| Serebruany, VL | 3 |
| Dinicolantonio, JJ | 1 |
| Can, MM | 1 |
| Goto, S | 1 |
| Silber, S | 1 |
| Barragan, P | 1 |
| Bouvier, JL | 1 |
| Roquebert, PO | 1 |
| Macaluso, G | 1 |
| Commeau, P | 1 |
| Comet, B | 1 |
| Lafont, A | 1 |
| Camoin, L | 1 |
| Walter, U | 2 |
| Eigenthaler, M | 1 |
| Aronow, HD | 1 |
| Cura, FA | 1 |
| Bhatt, DL | 2 |
| Albirini, A | 1 |
| Schneider, JP | 1 |
| Topol, EJ | 1 |
| Ellis, SG | 1 |
| Helft, G | 1 |
| Elalamy, I | 1 |
| Laudy, C | 1 |
| Tran, D | 1 |
| Beygui, F | 1 |
| Le Feuvre, C | 1 |
| Ounissi, F | 1 |
| Monnet de Lorbeau, B | 1 |
| Khellaf, C | 1 |
| Metzger, JP | 1 |
| Kopp, CW | 1 |
| Steiner, S | 1 |
| Priglinger, U | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Minar, E | 1 |
| Gaitonde, RS | 1 |
| Sharma, N | 1 |
| Ali-Hasan, S | 1 |
| Miller, JM | 1 |
| Jayachandran, JV | 1 |
| Kalaria, VG | 1 |
| Khambekar, SK | 1 |
| Kovac, J | 1 |
| Hong, MK | 2 |
| Mintz, GS | 2 |
| Lee, CW | 2 |
| Kim, YH | 2 |
| Lee, SW | 3 |
| Song, JM | 1 |
| Han, KH | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 2 |
| Park, SW | 2 |
| Moses, JW | 3 |
| Ludwig, J | 1 |
| Holmes, DR | 4 |
| Spanos, V | 1 |
| Louvard, Y | 1 |
| Desmedt, B | 1 |
| Di Mario, C | 1 |
| Leon, MB | 3 |
| Stouffer, GA | 1 |
| Hirmerova, J | 1 |
| Moll, S | 1 |
| Rubery, B | 1 |
| Napoli, M | 1 |
| Ohman, EM | 2 |
| Simpson, R | 1 |
| Juergens, CP | 1 |
| Wong, AM | 1 |
| Leung, DY | 1 |
| Lo, S | 1 |
| Fernandes, C | 1 |
| Newland, EF | 1 |
| Hopkins, AP | 1 |
| Berger, PB | 2 |
| Jiménez-Quevedo, P | 2 |
| Bernardo, E | 2 |
| Fernández-Ortiz, A | 1 |
| Barrera Ramírez, C | 1 |
| Fernandez, C | 2 |
| Hernández-Antolín, R | 2 |
| Escaned, J | 2 |
| Alfonso, F | 2 |
| Macaya, C | 2 |
| Patel, MR | 1 |
| Peterson, ED | 1 |
| Sekiguchi, M | 1 |
| Hoshizaki, H | 1 |
| Adachi, H | 1 |
| Ohshima, S | 1 |
| Taniguchi, K | 1 |
| Kurabayashi, M | 1 |
| Hashiguchi, M | 1 |
| Ohno, K | 1 |
| Nakazawa, R | 1 |
| Kishino, S | 1 |
| Mochizuki, M | 1 |
| Shiga, T | 1 |
| Sawhney, N | 1 |
| Kuntz, RE | 2 |
| Bachinsky, W | 1 |
| Bass, T | 1 |
| DeMaio, S | 1 |
| Fry, E | 1 |
| Teirstein, PS | 2 |
| Casselman, FP | 1 |
| Meco, M | 1 |
| Dom, H | 1 |
| Foubert, L | 1 |
| Van Praet, F | 1 |
| Vanermen, H | 1 |
| Akbulut, M | 1 |
| Ozbay, Y | 1 |
| Karaca, I | 1 |
| Ilkay, E | 1 |
| Gundogdu, O | 1 |
| Arslan, N | 1 |
| Rampp, T | 1 |
| Block, M | 1 |
| Berger, P | 1 |
| Grines, C | 1 |
| Weitz, JI | 1 |
| Sharma, SK | 1 |
| Choudhury, A | 1 |
| Lee, J | 1 |
| Kim, MC | 1 |
| Fisher, E | 1 |
| Steinheimer, AM | 1 |
| Kini, AS | 1 |
| Midei, MG | 1 |
| Malinin, AI | 1 |
| Oshrine, BR | 1 |
| Lowry, DR | 1 |
| Sane, DC | 1 |
| Tanguay, JF | 1 |
| Steinhubl, SR | 1 |
| O'Connor, CM | 1 |
| Hennekens, CH | 1 |
| Cox, N | 1 |
| Fitzpatrick, M | 1 |
| Douglas, J | 1 |
| Lambert, C | 1 |
| Mooney, M | 1 |
| Yakubov, S | 1 |
| Obergfell, A | 1 |
| Strotmann, J | 1 |
| Bonz, A | 1 |
| Bauersachs, J | 1 |
| Ertl, G | 1 |
| Grossmann, R | 1 |
| von Mach, MA | 1 |
| Eich, A | 1 |
| Weilemann, LS | 1 |
| Bliden, KP | 5 |
| Zaman, KA | 1 |
| Yoho, JA | 3 |
| Hayes, KM | 2 |
| Leopold, JA | 1 |
| Antman, EM | 1 |
| Herzog, WR | 1 |
| Aranki, S | 1 |
| Byrne, J | 1 |
| Bhatia, D | 1 |
| Mehta, S | 1 |
| Mills, R | 1 |
| Kunz, I | 1 |
| Spada, S | 1 |
| Sütsch, G | 1 |
| Ruggieri, F | 1 |
| Karvouni, E | 1 |
| Korovesis, S | 1 |
| Katritsis, DG | 1 |
| Wood, F | 1 |
| Bazemore, E | 1 |
| Schneider, JE | 1 |
| Jobe, RL | 1 |
| Mann, T | 1 |
| Biondi-Zoccai, GG | 2 |
| Chieffo, A | 1 |
| Vittori, G | 1 |
| Falchetti, E | 1 |
| Margheri, M | 1 |
| Barbagallo, R | 1 |
| Tamburino, C | 1 |
| Remigi, E | 1 |
| Briguori, C | 1 |
| Iakovou, I | 1 |
| Agostoni, P | 2 |
| Tsagalou, E | 1 |
| Melzi, G | 1 |
| Michev, I | 1 |
| Airoldi, F | 1 |
| Montorfano, M | 1 |
| Carlino, M | 1 |
| Rubboli, A | 1 |
| Milandri, M | 1 |
| Castelvetri, C | 1 |
| Cosmi, B | 1 |
| Cay, S | 1 |
| Yilmaz, MB | 1 |
| Korkmaz, S | 1 |
| Dibra, A | 1 |
| Braun, S | 1 |
| Hadamitzky, M | 1 |
| Baum, H | 1 |
| Dirschinger, J | 1 |
| Schühlen, H | 1 |
| Schömig, A | 1 |
| Biancari, F | 1 |
| Juvonen, T | 1 |
| Lengyel, M | 1 |
| Samara, W | 1 |
| Hayes, K | 1 |
| Fissha, MZ | 1 |
| Urban, P | 1 |
| Guagliumi, G | 1 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Wijns, W | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Vats, HS | 1 |
| Hocking, WG | 1 |
| Rezkalla, SH | 1 |
| Templin, C | 1 |
| Schaefer, A | 1 |
| Stumme, B | 1 |
| Drexler, H | 1 |
| von Depka, M | 1 |
| Schneider, H | 1 |
| Weber, F | 1 |
| Holzhausen, C | 1 |
| Körber, T | 1 |
| Ince, H | 1 |
| Rehders, T | 1 |
| Nienaber, CA | 1 |
| Kaya, D | 1 |
| Celik, A | 1 |
| Avsar, A | 1 |
| Guyer, K | 1 |
| Aggarwal, N | 1 |
| Nikas, DN | 1 |
| Kalef-Ezra, J | 1 |
| Katsouras, CS | 1 |
| Tsekeris, P | 1 |
| Bozios, G | 1 |
| Pappas, C | 1 |
| Naka, KK | 1 |
| Kotsia, A | 1 |
| Papamichael, N | 1 |
| Sideris, DA | 1 |
| Michalis, LK | 1 |
| Borgdorff, P | 1 |
| Tangelder, GJ | 1 |
| Paulus, WJ | 1 |
| Founztopoulous, E | 1 |
| Mavroudis, C | 1 |
| Nadar, SK | 1 |
| Gunning, MG | 1 |
| Yang, J | 1 |
| Wang, N | 1 |
| Zhang, X | 1 |
| Ling, F | 1 |
| Zhou, L | 1 |
| Ye, X | 1 |
| Lip, GY | 1 |
| Karpha, M | 1 |
| Pfisterer, M | 1 |
| Brunner-La Rocca, HP | 1 |
| Buser, PT | 1 |
| Rickenbacher, P | 1 |
| Hunziker, P | 1 |
| Mueller, C | 1 |
| Jeger, R | 1 |
| Bader, F | 1 |
| Osswald, S | 1 |
| Kaiser, C | 1 |
| Califf, RM | 1 |
| Dorval, JF | 1 |
| Soulez, G | 1 |
| Berry, C | 1 |
| Bonan, R | 1 |
| Lee, JS | 1 |
| Dunn, SP | 1 |
| Marshall, HM | 1 |
| Cohen, MG | 1 |
| Smyth, SS | 1 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Bañuelos, C | 1 |
| Moreno, R | 1 |
| Fernández-Avilés, F | 1 |
| Marzocchi, A | 1 |
| Saia, F | 1 |
| Piovaccari, G | 1 |
| Manari, A | 1 |
| Aurier, E | 1 |
| Benassi, A | 1 |
| Cremonesi, A | 1 |
| Percoco, G | 2 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| Guastaroba, P | 1 |
| Grilli, R | 1 |
| Maresta, A | 1 |
| Zavalloni, D | 1 |
| Belli, G | 1 |
| Rossi, M | 1 |
| Presbitero, P | 1 |
| Satish, B | 1 |
| Tressa, K | 1 |
| Harish, CR | 1 |
| Tomaszuk-Kazberuk, A | 1 |
| Sobkowicz, B | 1 |
| Usowicz-Szaryńska, M | 1 |
| Prokop, JB | 1 |
| Knapp, M | 1 |
| Sawicki, R | 1 |
| Musiał, WJ | 1 |
| Lee, BK | 1 |
| Park, DW | 1 |
| Jang, S | 1 |
| Chi, HS | 1 |
| Campo, G | 1 |
| Valgimigli, M | 3 |
| Gemmati, D | 1 |
| Catozzi, L | 1 |
| Frangione, A | 1 |
| Federici, F | 1 |
| Ferrari, F | 1 |
| Tebaldi, M | 1 |
| Luccarelli, S | 1 |
| Parrinello, G | 1 |
| Ferrari, R | 1 |
| Sezer, M | 1 |
| Umman, B | 1 |
| Okcular, I | 1 |
| Nisanci, Y | 1 |
| Umman, S | 1 |
| Lotrionte, M | 1 |
| Abbate, A | 1 |
| Moretti, C | 1 |
| Meliga, E | 1 |
| Cuisset, T | 1 |
| Alessi, MC | 1 |
| Montalescot, G | 1 |
| Collet, JP | 1 |
| Testa, L | 1 |
| Sangiorgi, G | 1 |
| Laudito, A | 1 |
| Trevi, GP | 1 |
| Sheiban, I | 1 |
| de Korte, FI | 1 |
| van Werkum, JW | 1 |
| Vijverberg, PL | 1 |
| Ten Berg, JM | 1 |
| De Meyer, SF | 1 |
| Staelens, S | 1 |
| Badenhorst, PN | 1 |
| Pieters, H | 1 |
| Lamprecht, S | 1 |
| Roodt, J | 1 |
| Janssens, S | 1 |
| Meiring, M | 1 |
| Vanhoorelbeke, K | 1 |
| Bruwer, A | 1 |
| Brown, S | 1 |
| Deckmyn, H | 1 |
| Bruschi, G | 1 |
| Colombo, P | 1 |
| Piccalò, G | 1 |
| Trunfio, S | 1 |
| Colombo, T | 1 |
| Vitali, E | 1 |
| Price, MJ | 1 |
| Endemann, S | 1 |
| Gollapudi, RR | 1 |
| Valencia, R | 1 |
| Stinis, CT | 1 |
| Levisay, JP | 1 |
| Ernst, A | 1 |
| Sawhney, NS | 1 |
| Schatz, RA | 1 |
| Lev, EI | 1 |
| Kornowski, R | 1 |
| Vaknin-Assa, H | 1 |
| Brosh, D | 1 |
| Fuchs, S | 1 |
| Battler, A | 1 |
| Assali, A | 1 |
| Zürn, CS | 1 |
| Paterok, M | 2 |
| Gawaz, M | 2 |
| Zürn, C | 1 |
| Göhring-Frischholz, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| Seizer, P | 1 |
| Kraemer, BF | 1 |
| Dippon, J | 1 |
| May, AE | 1 |
| Herdeg, C | 1 |
| Kollum, M | 1 |
| Bhargava, B | 1 |
| Kent, KM | 1 |
| Kolodgie, FD | 1 |
| Virmani, R | 1 |
| Kumar, RK | 1 |
| Chesterman, CN | 1 |
| Fahmy, RG | 1 |
| Khachigian, LM | 1 |
| Placci, A | 1 |
| Melandri, G | 1 |
| Cecilioni, L | 1 |
| Bolondi, L | 1 |
| Branzi, A | 1 |
| Hasa, AA | 1 |
| Schmaier, AH | 1 |
| Warnock, M | 1 |
| Normolle, D | 1 |
| Driscoll, E | 1 |
| Lucchesi, BR | 1 |
| Werns, SW | 1 |
| Piamsomboon, C | 1 |
| Laothavorn, P | 1 |
| Chatlaong, B | 1 |
| Saguanwong, S | 1 |
| Nasawadi, C | 1 |
| Tanprasert, P | 1 |
| Leelaprute, M | 1 |
| Intayakorn, U | 1 |
| Amornsak, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI[NCT00976092] | Phase 4 | 548 participants (Actual) | Interventional | 2009-09-30 | Active, not recruiting | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement[NCT00457236] | 800 participants | Observational | 2003-03-31 | Active, not recruiting | |||
| Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion[NCT00794014] | 258 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| 150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention[NCT00638326] | Phase 3 | 500 participants (Anticipated) | Interventional | 2008-03-31 | Terminated (stopped due to Greater differences between randomized patients than previously anticipated) | ||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372] | Phase 4 | 150 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186] | Phase 4 | 190 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671] | Phase 4 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693] | Phase 4 | 80 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| ABILITY Diabetes Global[NCT04236609] | 3,050 participants (Actual) | Interventional | 2020-06-15 | Active, not recruiting | |||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771] | Phase 4 | 44 participants (Anticipated) | Interventional | 2007-11-30 | Not yet recruiting | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
| Intervention | US dollars (Mean) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 5483 |
| Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
| Intervention | vessels (Number) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 14 |
| Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| MACCE | Death | Acute Myocardial Infarction | Stroke | |
| Drug Eluting Stents | 15 | 7 | 9 | 1 |
| Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
10 reviews available for ticlopidine and Coronary Stenosis
| Article | Year |
|---|---|
[2017 Update on dual antiplatelet therapy: what's new?]
Topics: Advisory Committees; Aged; Aspirin; Coronary Angiography; Coronary Stenosis; Dose-Response Relations | 2018 |
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2008 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindic | 2004 |
Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; C | 2005 |
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2005 |
[Triplex antithrombotic therapy after coronary-stent implantation (that is absent from recommendation)].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Coumarins; Drug Ther | 2005 |
[Dual antithrombotic therapy after implantation of coronary stents].
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; P | 2006 |
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Drug Administration Schedul | 2007 |
30 trials available for ticlopidine and Coronary Stenosis
| Article | Year |
|---|---|
Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment.
Topics: Adult; Aged; Aspirin; Blood Platelets; Catechin; Clopidogrel; Coronary Stenosis; Female; Humans; Mal | 2018 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; C | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combinatio | 2014 |
A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2014 |
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; | 2016 |
Prevalence and Predictors of Early Discontinuation of Dual-Antiplatelet Therapy After Drug-Eluting Stent Implantation in Korean Population.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationshi | 2016 |
Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Coron | 2009 |
Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Dose-Re | 2009 |
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Embolism; Female; H | 2010 |
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Confidence | 2010 |
Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase | 2011 |
Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Elective | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2011 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Prediction of significant left main coronary artery stenosis by the 12-lead electrocardiogram in patients with rest angina pectoris and the withholding of clopidogrel therapy.
Topics: Adult; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Coronary Stenosis; Electrocardiogr | 2003 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity; | 2004 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; | 2004 |
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
Topics: Aged; Cilostazol; Coronary Restenosis; Coronary Stenosis; Equipment Design; Female; Follow-Up Studie | 2004 |
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary | 2004 |
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2004 |
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen | 2005 |
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Femal | 2005 |
Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
Topics: Aged; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coronary Stenosis; Dose-Response Rela | 2007 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli | 2006 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno | 2007 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Drug Therapy, C | 2001 |
107 other studies available for ticlopidine and Coronary Stenosis
| Article | Year |
|---|---|
Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stent | 2013 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary T | 2013 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D | 2013 |
The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Female; Fractional F | 2013 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2015 |
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2014 |
Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drug-eluting coronary stent implantation.
Topics: Aged; Aspirin; Benzamides; Chemotherapy, Adjuvant; Clopidogrel; Coronary Stenosis; Drug-Eluting Sten | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vess | 2015 |
Two young women with severe coronary arterial ostial narrowing: A potential subtype of Takayasu arteritis.
Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Cyclophosphamide; Diagnosis, D | 2015 |
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog | 2015 |
Long-term Outcomes of Medical Therapy Versus Coronary Revascularisation in Patients with Intermediate Stenoses Guided by Pressure Wire.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; Female; Follow-Up S | 2015 |
Predictors for Side Branch Failure During Provisional Strategy of Coronary Intervention for Bifurcation Lesions (from the Korean Bifurcation Registry).
Topics: Aged; Calcinosis; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Cor | 2016 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay.
Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel | 2008 |
A threshold of platelet reactivity for ischaemic events?
Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Very late stent thrombosis after discontinuation of clopidogrel therapy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studi | 2008 |
Re: Fleur I. de Korte, Jochem W. van Werkum, Peter L.M. Vijverberg, Jurriën M. ten Berg. Late coronary stent thrombosis complicating urologic surgery. Eur Urol 2008;54:221-5.
Topics: Coronary Stenosis; Drug-Eluting Stents; Humans; Lymph Node Excision; Male; Platelet Aggregation Inhi | 2009 |
Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Stenosis | 2008 |
Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Animals; Aspirin; Cell Proliferation; Clopido | 2008 |
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Case-Control Studies; Cell Adhesion | 2008 |
Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?
Topics: Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Clopidogrel; Coronary Restenosis; Coronary | 2008 |
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ | 2010 |
Athero-embolic isolated splenic infarction following left cardiac catheterization.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Atherosclerosis | 2009 |
The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
Topics: Aged; Clopidogrel; Coronary Stenosis; Drug Administration Schedule; Drug-Eluting Stents; Female; Fol | 2009 |
Drug-eluting coronary stents: many meta-analyses, little benefit.
Topics: Angina, Unstable; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Co | 2009 |
Spontaneous spinal epidural hematoma: an urgent complication of adding clopidogrel to aspirin therapy.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Decompression, Surgical; Drug Interactions; Hematoma, Epidu | 2009 |
Impact of clopidogrel use on mortality and major bleeding in patients undergoing coronary artery bypass surgery.
Topics: Analysis of Variance; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Cor | 2010 |
Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Antithrombins; Aspirin; beta-Thromboglobulin; Blood C | 2010 |
Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary St | 2010 |
Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; CD11b Antigen; Clopidogrel; Coronary Artery Disease; Coronary Stenos | 2011 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi | 2010 |
Plaque distribution in clopidogrel responders and low responders as determined by multislice computed tomography.
Topics: Aged; Calcinosis; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Resistance; Female; Ger | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Stenosis; Cytochrome P-450 CYP2C19; Drug Resist | 2011 |
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cause of Death; Clop | 2011 |
Feasibility and safety of 7-Fr radial approach for complex PCI.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu | 2011 |
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle | 2012 |
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos | 2011 |
Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.
Topics: Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Coronary Stenosis; Disease-Free | 2013 |
Simultaneous subacute thrombosis of bare metal coronary stents in two different arteries early after clopidogrel cessation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coron | 2012 |
Long-term successful percutaneous coronary intervention in factor VII deficiency.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Diabetes M | 2012 |
Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Dr | 2012 |
Deliverability of integrity coronary stents in severely tortuous coronary arteries: a preliminary experience.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Vessels; Female; Human | 2012 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic | 2013 |
[Off-label use of clopidogrel after coronary stent implantation in Germany: optional or mandatory?].
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Approval; Drug Costs; Drug Prescr | 2003 |
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio | 2003 |
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Dose- | 2003 |
[Clopidogrel and thrombopenia. A case report].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Humans; Male; | 2003 |
Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug Erup | 2004 |
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona | 2004 |
Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura.
Topics: Aged; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Eptifibat | 2004 |
Resistance to antiplatelet drugs: is it real or relevant?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid | 2004 |
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; | 2004 |
Paclitaxel-eluting coronary stents.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Humans; Paclita | 2004 |
Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
Topics: Aged; Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Sten | 2004 |
Clopidogrel dosing in overweight patients: does one size fit all?
Topics: Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Stenosis; | 2004 |
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona | 2004 |
[How does it work? Coronary stent implantation].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Drug T | 2004 |
Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; Blood Vessel Pr | 2004 |
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Vessel Prosthesis Implantation; | 2004 |
Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Stenosis; Cyclic AMP; Humans; Male; Mi | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A | 2005 |
[Exercise-induced left arm pain and thrombocytosis].
Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary | 2005 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
Technique of left main stenting is dependent on lesion location and distal branch protection.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coated Mate | 2005 |
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era.
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantati | 2005 |
Intracranial bleeding associated with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Clopidogrel; Coronary Stenosis; Human | 2005 |
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
Topics: Abciximab; Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Mono | 2005 |
Does clopidogrel improve the long-term outcome after coronary artery bypass surgery?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Coronary Stenosis; Humans; Platelet Aggreg | 2005 |
What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Humans; P | 2005 |
Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
Topics: Aged; Clopidogrel; Coronary Stenosis; Female; Humans; Male; Middle Aged; Platelet Activation; Stents | 2005 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Spontaneous or clopidogrel related recanalisation of a coronary artery.
Topics: Clopidogrel; Coronary Angiography; Coronary Stenosis; Humans; Male; Middle Aged; Myocardial Infarcti | 2006 |
Long-term clinical outcome of patients treated with beta-brachytherapy in routine clinical practice.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studi | 2007 |
Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
Topics: Animals; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Stenosis; Cyclooxygenase Inhibitors; | 2006 |
Case report: An unusual complication of clopidogrel.
Topics: Clopidogrel; Coronary Stenosis; Hallucinations; Humans; Male; Middle Aged; Platelet Aggregation Inhi | 2007 |
Late angiographic stent thrombosis in a drug-eluting stent that occurred 20 months after premature discontinuation of clopidogrel administration.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Humans; Male; Plat | 2006 |
Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2006 |
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
Topics: Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunosuppressiv | 2006 |
Management of a spontaneous renal capsule hematoma following cardiac catheterization involving use of a platelet glycoprotein IIb/IIIa inhibitor: a case report.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Catheterization; Clopidogrel; Cor | 2007 |
A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resi | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi | 2007 |
Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary | 2007 |
Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Disease Progression; Drug H | 2007 |
[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report].
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombos | 2007 |
Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary An | 2007 |
Relationship between microvascular resistance and perfusion in patients with reperfused acute myocardial infarction.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Coronary Stenosis; | 2007 |
Late coronary stent thrombosis complicating urologic surgery.
Topics: Aged; Clopidogrel; Coronary Stenosis; Drug-Eluting Stents; Fatal Outcome; Humans; Immunosuppressive | 2008 |
Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor--collagen interaction in baboons.
Topics: Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Aspirin; Clopidogrel; Collagen; Cor | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Successful emergent surgical revascularization and retrieval of entrapped drug eluting stent.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Sten | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut | 2008 |
Switching thienopyridines: hypothetical versus real risks.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Dr | 2008 |
Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary St | 2008 |
Resistance to what, does it matter? How do we study it?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance | 2008 |
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvas | 2008 |
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Stenosis; Cytochrome P-450 CYP3A; Dru | 2008 |
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Com | 2001 |
Coronary stent thrombosis: insights from the porcine coronary stent model.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess | 2001 |
[Late-appearing cholestatic icterus after a month of treatment with ticlopidine].
Topics: Aged; Angioplasty, Balloon, Coronary; Chemical and Drug Induced Liver Injury; Coronary Stenosis; Hum | 2001 |
Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
Topics: Animals; Aspirin; Blood Coagulation Tests; Bradykinin; Clopidogrel; Coronary Stenosis; Coronary Thro | 2001 |